Home > News > Industry > Pharma News > Serum Institute seeks...

Serum Institute seeks DCGI emergency use nod for rBCG tuberculosis vaccine

By - Ruchika Sharma
Published On 2022-03-28 06:30 GMT   |   Update On 2024-02-16 11:26 GMT

New Delhi: The Serum Institute has applied to the Drugs Controller General of India seeking emergency use authorisation for its recombinant BCG (rBCG) vaccine for the prevention of tuberculosis, official sources said on Sunday. The EUA application was submitted on March 22 by Prakash Kumar Singh, Director of Government and Regulatory Affairs at the Serum Institute of India (SII).India's...

Login or Register to read the full article
Register Now

New Delhi: The Serum Institute has applied to the Drugs Controller General of India seeking emergency use authorisation for its recombinant BCG (rBCG) vaccine for the prevention of tuberculosis, official sources said on Sunday. The EUA application was submitted on March 22 by Prakash Kumar Singh, Director of Government and Regulatory Affairs at the Serum Institute of India (SII).

India's TB immunisation programme currently offers BCG vaccination at birth or as early as possible till one year of age.
SII already supplies life-saving vaccines to the government under the Universal Immunisation Programme, including Pneumococcal, IPV and Rotavirus, Singh mentioned in his letter.
The Pune-based firm is one of the companies which supply BCG vaccine to the government.
"Our government is committed to eliminate TB. The vision of TB-free India has been energised by the clarion call of the prime minister to end TB from our country by 2025 , five years ahead of the Sustainable Development Goal of ending TB," Singh mentioned in his letter.
"Under leadership of our CEO Adar C Poonawalla, our firm is committed to make available a safe, efficacious and high-quality world class TUBERVAC-rBCG vaccine for newborns, children, adolescents and adults at affordable price," an official source quoted Singh as having said in the application.
Recombinant BCG vaccines are manufactured through advanced technology that allows the insertion of foreign genes, or overexpression of native genes, into the BCG vaccine, an official explained.
The number of tuberculosis cases in India has seen a 19 per cent rise in 2021 over the previous year, and there has been an increase in the mortality rate due to all forms of TB between 2019 and 2020 by 11 per cent, according to the annual TB report released by Union Health Minister Mansukh Mandaviya on Thursday.
Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Bayer, Evotec ink pact to advance precision cardiology
Janssen to adopt Johnson & Johnson brand in UK
Boehringer Ingelheim gets USFDA nod for high-concentration, citrate-free formulation of Cyltezo to treat multiple chronic inflammatory diseases
Alkem Laboratories Gets CDSCO Panel Nod to Study Amoxicillin,Clavulanate Powder for reconstitution into suspension
Bharat Biotech Chief Dr Krishna M Ella named as new President of Indian Vaccine Manufacturers Association
Pneubevax 14 safe, immunogenic in 6-8 week old infants: Biological E
Sun Pharma served with tax demand of Rs 1.11 crore
AstraZeneca Truqap plus Faslodex recommended for approval in EU by CHMP for advanced ER-positive breast cancer